Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

    NEXT STORY
    Carrier Screening Market to Grow With 10.9% CAGR in Coming Years: P&S Intelligence
    PREV STORY
    Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    NewLink Genetics Corporation Provides Operational Update and Reports Third Quarter 2016 Financial Results

    AMES, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company ...

    author_avatar
    NASDAQ Market News

    Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

    author_avatar
    NASDAQ Market News

    Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study

    author_avatar
    NASDAQ Market News